Search

Search Results

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2743

  PDF: 1687

  HTML: 738

• IRON METABOLISM IN THALASSEMIA AND SICKLE CELL DISEASE

  Raffaella Mariani, Paola Trombini, Matteo Pozzi, Alberto Piperno

  e2009006

  2009-10-27

  1778

  PDF: 717

  HTML: 43974

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3915

  PDF: 1382

  HTML: 2192

  Fig.1: 293

  Fig. 2: 272

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1769

  PDF: 529

  HTML: 1589

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3263

  PDF: 1113

  HTML: 1674

• JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia

  Phakatip Sinlapamongkolkul, Pacharapan Surapolchai, Vip Viprakasit

  e2023056

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.056

  3456

  PDF: 683

  Suppl. Files: 333

  HTML: 323

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  3318

  PDF: 1704

  HTML: 408

• QUANTITATIVE ANALYSIS OF LIVER IRON DEPOSITION BASED ON DUAL-ENERGY CT IN THALASSEMIA PATIENTS

  Fengming Xu, Cheng Tang, Yiling Huang, Linlin Liang, Fuling Huang, Gaohui Yang, Peng Peng

  e2023020

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.020

  1125

  PDF: 982

  HTML: 461

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4365

  PDF: 1313

  HTML: 1496

• TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS

  SOPHIA DELICOU

  e2018049

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.049

  1706

  PDF: 933

  HTML: 255

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1394

  PDF: 665

  HTML: 2351

• LIVER IRON CONTENT (LIC) IN ADULTS WITH NON-TRANSFUSION DEPENDENT SICKLE CELL DISEASE (NT-SCD). CORRELATION WITH SERUM FERRITIN AND LIVER ENZYMES CONCENTRATIONS

  Vincenzo De Sanctis

  e2017037

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.037

  4160

  PDF: 1077

  HTML: 1223

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2887

  PDF: 903

  HTML: 15038

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 382

• SALIVA IRON AND FERRITIN LEVELS IN PATIENTS WITH THALASSEMIA AND IRON DEFICIENCY ANEMIA

  Duran Canatan, Sevgi Kosaci Akdeniz

  e2012051

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.051

  3220

  PDF: 1553

  HTML: 10963

• PREDISPOSING FACTORS TO INFECTIONS IN THALASSEMIA SYNDROME PATIENTS

  Eman M Mansory, Lina M. Abdulrahman, Balsam Osman, Sawsan M. Sawsan, Assil F. Ruckn, Marwa Aljedaani, Nemmat Hassan, Ahmed S. Barefah, Hatem M. Alahwal, Yassir Daghistani, Salem M. Bahashwan, Abdullah T. Almohammadi, Osman O. Radhwi

  e2025055

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.055

  1977

  PDF: 1638

  HTML: 516

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  4155

  PDF: 1226

  HTML: 477

• ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?

  Vincenzo De Sanctis

  e2016001

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.001

  5697

  PDF: 1382

  HTML: 3690

• ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY

  Deniz Guven, Dr. İncefidan, Dr. Kazanci, Dr. Ozlem Kara

  e2026017

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.017

  840

  PDF: 747

  HTML: 195

• CLINICAL IMPACT OF ELTROMBOPAG-ASSOCIATED IRON CHELATION IN ADULTS WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER REAL-WORLD STUDY

  Ahmet Yigitbasi, Elif Gulsum Umit, Ufuk Demirci, Guray Aygun, Nese Varli, Elif Aksoy, Fehmi Hindilerden, Emine Gulturk, Eren Arslan Davulcu, Ahmet Muzaffer Demir

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.027

  1046

  PDF: 918

  HTML: 220

• THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS

  Gehan Lotfy Abdel Hakeem, hoda Abdel kereem Abdel Samei, Ashraf mohamed El Shereif, Ahlam mohamed ismail

  e2015023

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.023

  2342

  PDF: 1058

  HTML: 3074

  Untitled: 281

• CLINICAL AND BIOCHEMICAL DATA OF ADULT THALASSEMIA MAJOR PATIENTS (TM) WITH MULTIPLE ENDOCRINE COMPLICATIONS (MEC) VERSUS TM PATIENTS WITH NORMAL ENDOCRINE FUNCTIONS: A RETROSPECTIVE LONG-TERM STUDY (40 YEARS) IN A TERTIARY CARE CENTER IN ITALY

  Vincenzo De Sanctis, Heba Elsedfy

  e2016022

  2016-04-12

  https://doi.org/10.4084/mjhid.2016.022

  5019

  PDF: 1122

  HTML: 3577

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  2333

  PDF: 1537

  HTML: 263

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2402

  PDF: 2241

  HTML: 2593

• NATURAL HISTORY OF GLUCOSE HOMEOSTASIS AND AND Β-CELL FUNCTION FROM CHILDHOOD TO EARLY ADULTHOOD IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: A NINE-YEAR LONGITUDINAL COHORT STUDY

  Vincenzo De Sanctis, Ashraf T Soliman, Shahina Daar, Mohammad Faranoush, Ploutarchos Tzoulis

  e2026089

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.089

  2

  PDF: 2

  Html: 2

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1772

  PDF: 576

  HTML: 282

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2959

  PDF: 1488

  HTML: 377

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2813

  PDF: 1291

  HTML: 454

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  2066

  PDF: 1047

  HTML: 413

• GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS

  Naouel GUIRAT

  e2018031

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.031

  5977

  PDF: 1104

  HTML: 494

  TABLE: 236

  FIGURES: 325

• CORRELATION OF TRANSIENT ELASTOGRAPHY WITH LIVER IRON CONCENTRATION, AND SERUM FERRITIN LEVELS IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA MAJOR PATIENTS FROM OMAN

  Hammad Khan, Vinodh Panjwani, Sara Al Rahbi, Abubakr Eltigani , Rizwan Qureshi, Khaleeq Unnisa, Najmus Sehar, Alok Mittal, Anil Pathare

  e2023048

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.048

  1327

  PDF: 794

  HTML: 275

• EXERCISE STRESS ECHOCARDIOGRAPHY WITH TISSUE DOPPLER IMAGING (TDI) DETECTS EARLY SYSTOLIC DYSFUNCTION IN BETA-THALASSEMIA MAJOR PATIENTS WITHOUT CARDIAC IRON OVERLOAD

  Umberto Barbero

  e2012037

  2012-06-14

  https://doi.org/10.4084/mjhid.2012.037

  1473

  PDF: 877

  HTML: 7894

  Manuscript after revision: 288

  Barbero10328-36310-after revision: 288

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2442

  PDF: 1021

  HTML: 405

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2266

  PDF: 1239

  HTML: 2027

• THALASSAEMIA INTERMEDIA : AN UPDATE

  Ali Taher, Khaled M. Musallam, Maria Domenica Cappellini

  e2009004

  2009-08-17

  1163

  PDF: 482

  HTML: 9487

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4465

  PDF: 1618

  HTML: 483

• THALASSAEMIA AND ABERRATIONS OF GROWTH AND PUBERTY

  Andreas Kyriakou, Nicos Skordis

  e2009003

  2009-07-28

  1292

  PDF: 505

  HTML: 3342

• THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.

  Sanaa Kamal, Sara Abdelhakam, Dr., Dahlia Ghoraba, Mohamad Amer Mohsen, Ahmed Abdelsalam, Huda Hassan, Leila Nabeigh

  e2019060

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.060

  1604

  PDF: 1129

  HTML: 229

• Congenital Atypical Microcytic Anemia Accompanied by Iron Deficiency and Accumulation

  mustafa özay, zafer bıçakçı

  e2022070

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.070

  1043

  PDF: 656

  HTML: 369

• COMPARATIVE STUDY ON THE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA PATIENTS AND THE CLINICAL GRADING OF LIVER IRON CONCENTRATION BY DIFFERENT POST-PROCESSING SOFTWARE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA

  Peng Peng, Fengming XU, Jixing YI, Bumin LIANG, Cheng TANG, Qing FENG

  e2022072

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.072

  2459

  PDF: 694

  HTML: 351

• A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.

  SALVATORE DI MAIO, VINCENZO DE SANCTIS, PIERLUIGI MARZUILLO, CHRISTOS KATTAMIS, SHAHINA DAAR, MEHERAN KARIMI, SAKI FOROUGH, ATANAS BANKEV, VALERIA KALEVA, SOTEROULA CHRISTOU, CARMELO FORTUGNO, POLYXENI DELAPORTA, ASHRAF T SOLIMAN , PLOUTARCHOS TZOULIS

  e2023058

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.058

  925

  PDF: 626

  HTML: 192

• TRANSFUSION PRACTICE, POST-TRANSFUSION COMPLICATIONS AND RISK FACTORS IN SICKLE CELL DISEASE IN SENEGAL, WEST AFRICA.

  Moussa Seck, Alioune Badara Senghor, Mossane Loum, Sokhna Aissatou Touré, Blaise Félix Faye, Alioune Badara Diallo, Mohamed Keita, Elimane Seydi Bousso, Sérigne Mourtalla Guèye, Macoura Gadji, Abibatou Sall, Awa Oumar Touré, Saliou Diop

  e2022004

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.004

  2175

  PDF: 1190

  HTML: 486

• THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis

  Kun Yang, Jian Xiao

  e2024001

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.001

  1560

  PDF: 1525

  PDF: 1111

  HTML: 239

• THE DIAGNOSTIC VALUE OF PULSED WAVE TISSUE DOPPLER IMAGING IN ASYMPTOMATIC BETA- THALASSEMIA MAJOR CHILDREN AND YOUNG ADULTS ; RELATION TO CHEMICAL BIOMARKERS OF LEFT VENTRICULAR FUNCTION AND IRON OVERLOAD .

  Seham Ragab

  e2015051

  2015-08-24

  https://doi.org/10.4084/mjhid.2015.051

  1528

  PDF: 944

  HTML: 1461

  Untitled: 236

• THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN

  Sara Matin, Masoud Ghanei Jahromi, Zohreh Karemizadeh, Sezaneh Haghpanah, Vincenzo De Sanctis, Ashraf Soliman, Mehran Karimi

  e2015005

  2014-08-28

  https://doi.org/10.4084/mjhid.2015.005

  2459

  PDF: 1162

  HTML: 9700

• ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS

  George Petrikkos, Miranda Drogari-Apiranthitou

  e2011012

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.012

  3049

  PDF: 1053

  HTML: 7523

• AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging

  Dr.Sophia Delicou, Dr.Ioannis Ilias, Dr.Athanasia Kapota, Dr.Elena Papatheodorou, Dr.Maria Moraki, Dr.Aikaterini Xydaki, Dr.Alexandra Mika, Dr.Panagiota Giannou, Dr.Irene Kouroukli, Dr.Theodoros Aforozis, Dr.Myrto Palkopoulou, Dr.Christos Savvidis, Dr.Iliana Mani, Prof.Constantina Aggeli, Prof. John Koskinas

  e2026039

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.039

  647

  PDF: 656

  Suppl. Files: 84

  HTML: 173

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1475

  PDF: 1039

  HTML: 348

• INFECTIONS IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Bianca Maria Ricerca, Arturo Di Girolamo, Deborah Rund

  e2009028

  2009-12-28

  1489

  PDF: 702

  HTML: 4470

• HEALTH-RELATED QUALITY OF LIFE IN THAI CHILDREN WITH THALASSEMIA AS EVALUATED BY PEDSQL AND EQ-5D-Y: A SINGLE CENTER EXPERIENCE

  Pacharapan Surapolchai, Phakatip Sinlapamongkolkul

  e2020036

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.036

  1694

  PDF: 1236

  HTML: 390

• STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .

  Seham Ragab, Manal A. Safan, Eman A. Badr

  e2015019

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.019

  2544

  PDF: 1249

  HTML: 2631

  Study of serum haptoglobin level in thalassemia: 454

  Figures: 278